Horizon Therapeutics (NASDAQ: HPTX) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Horizon Therapeutics to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.
This table compares Horizon Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Horizon Therapeutics Competitors||-13,486.12%||-54.03%||-24.46%|
This table compares Horizon Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Horizon Therapeutics Competitors||$584.27 million||$101.79 million||61.04|
Horizon Therapeutics’ competitors have higher revenue and earnings than Horizon Therapeutics. Horizon Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings for Horizon Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Horizon Therapeutics Competitors||158||831||1816||61||2.62|
As a group, “Biopharmaceuticals” companies have a potential upside of 0.89%. Given Horizon Therapeutics’ competitors higher probable upside, analysts plainly believe Horizon Therapeutics has less favorable growth aspects than its competitors.
Institutional & Insider Ownership
42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Horizon Therapeutics competitors beat Horizon Therapeutics on 5 of the 8 factors compared.
About Horizon Therapeutics
Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company’s products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.